Four-Pronged attack on incurable blood cancer shows promise
NCT ID NCT04113018
Summary
This study is testing a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma, a cancer of the blood. The goal is to see how well this intensive treatment works to control the disease and achieve a deep response. Researchers will also track how long the treatment keeps the cancer in check and use special tests to guide further therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.